AvMed

PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

<u>Directions</u>: <u>The prescribing physician must sign and clearly print name (preprinted stamps not valid)</u> on this request. All other information may be filled in by office staff; <u>fax to 1-305-671-0200</u>. No additional phone calls will be necessary if all information (<u>including phone and fax #s</u>) on this form is correct. <u>If the information provided is not complete, correct, or legible, the authorization process can be delayed.</u>

Drug Requested: Exxua[™] (gepirone)

MEMBER & PRESCRIBER INFORMATION: Authorization may be delayed if incomplete.			
Meml	ber Name:		
Member Sentara #:		Date of Birth:	
Presci	riber Name:		
Prescriber Signature:		Date:	
Office	e Contact Name:		
Phone Number:		Fax Number:	
NPI #	#:		
DRU	UG INFORMATION: Authorizati	on may be delayed if incomplete.	
Drug	Name/Form/Strength:		
Dosing Schedule:		Length of Therapy:	
Diagn	10sis:	ICD Code, if applicable:	
Weight (if applicable):		Date weight obtained:	
Reco	ommended Dosage: One tablet per o	day. Maximum dosage: 72.6 mg once daily.	
suppo		v all that apply. All criteria must be met for approval. To a, including lab results, diagnostics, and/or chart notes, must be	
	, c	d meets <u>ONE</u> of the following dosing requirements:	
	 □ 18 to 64 years of age, maximum da □ ≥ 65 years of age, maximum daily 		
		•	
_	Member has a diagnosis of major depr appropriate depression rating scale (e.g	essive disorder (MDD) as defined by DSM-5 criteria and/or p. PHQ-9, Clinically Useful Depression Outcome Scale, Quick pgy-Self Report 16 Item, MADRS, HAM-D) (scale must be	

Member has failed non-pharmacological interventions such as cognitive behavioral therapy or interpersonal psychotherapy (submit documentation)	
Provider attests that member has been screened for personal and/or family history of bipolar disorder, mania, and hypomania	
Provider attests an electrocardiogram (ECG) will be performed before starting treatment, during dosage titration, and periodically during treatment	
Provider attests electrolyte abnormalities will be corrected prior to initiation	
Provider attests members with electrolyte abnormalities, who are receiving diuretics or glucocorticoids or have a history or hypokalemia or hypomagnesemia will be monitored during dose titration and periodically during treatment	
Member does NOT have any of the following:	
• Hypersensitivity to gepirone or any component of the requested medication	
• Prolonged QTc interval greater than 450 msec	
Congenital long QT syndrome	
• Use of strong CYP3A4 inhibitors	
Severe liver problems	
Member will <u>NOT</u> take a monoamine oxidase inhibitor (MAOI) within 14 days of taking Exxua [™]	
Member has tried and failed <u>THREE</u> (3) formulary antidepressants, including one (1) selective serotonin reuptake inhibitor (SSRI), one (1) serotonin-norepinephrine reuptake inhibitor (SNRI), and one (1) other agent (e.g., bupropion, mirtazapine, TCA) for at least <u>30 days</u> (verified by chart notes and/or pharmacy paid claims)	
Member has tried and failed <u>ONE</u> (1) other pharmacotherapy for combination or augmentation (e.g., lithium, liothyronine, buspirone, antipsychotics, anticonvulsants) for at least <u>30 days</u> (verified by chart notes and/or pharmacy paid claims)	

Not all drugs may be covered under every Plan

If a drug is non-formulary on a Plan, documentation of medical necessity will be required.

**Use of samples to initiate therapy does not meet step edit/ preauthorization criteria. **

*Previous therapies will be verified through pharmacy paid claims or submitted chart notes. *